Cetuximab in der first-line-therapie des kolonkarzinoms: Neue studie zeigt erstmals ein medianes überleben von 30 monaten
Research output: Contribution to journal › Comment/Debate › Contributed › peer-review
Contributors
Translated title of the contribution | Cetuximab in the first-line therapy of colon cancer A new study shows for the first time a median survival of 30 months |
---|
Details
Original language | German |
---|---|
Pages (from-to) | XII |
Journal | Klinikarzt : Medizin im Krankenhaus |
Volume | 34 |
Issue number | 10 |
Publication status | Published - 2005 |
Peer-reviewed | Yes |
External IDs
ORCID | /0000-0002-9321-9911/work/142251997 |
---|